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To the Editor:
Regarding the argument pre-
sented by Sculier et al.,1 predictive 
factors for determining which patients 
may benefit from adjuvant chemo-
therapy are important. Currently, the 
pathological stage based on tumor, 
node, metastasis (TNM) classification 
of surgical specimens is the only fac-
tor used. On the basis of the results of 
multiple randomized trials and meta-
analyses, patients treated according to 
the pathological stage are presumed 
to have better survival with adju-
vant chemotherapy than with surgery 
alone. Thus, to determine the setting 
in which adjuvant chemotherapy is 
applicable, TNM classification is 
used as a predictive factor. In addi-
tion to the pathological stage, some 
biological markers such as excision 
repair cross-complementing 12 are 
reported to be promising as predictive 
markers, but these are not yet used 
in clinical practice. In the manage-
ment of advanced lung cancer, bio-
logical markers such as mutation of 
epidermal growth factor receptor and 
translocation of echinoderm micro-
tubule-associated protein-like 4 gene 
and the anaplastic lymphoma kinase 
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We previously reported a case 
with epidermal growth factor receptor 
(EGFR)-mutant non–small-cell lung 
cancer where gefitinib rechallenge 
was effective after disappearance of 
T790M.1 “Temporal” T790M heteroge-
neity had been demonstrated in the pre-
vious report, whereas “spatial” T790M 
heterogeneity was also shown in the 
same patient.
After progression on gefi-
tinib rechallenge, he underwent 
pemetrexed with stable disease. Six 
months after gefitinib discontinua-
tion, rebiopsy was performed again. 
T790M mutation was still detected. 
He then received S-1, gemcitabine, 
and docetaxel, sequentially. A further 
6 months later, we repeated rebiopsy 
for both the primary tumor for which 
rebiospsy was done previously several 
times and a newly progressed pulmo-
nary metastasis. T790M was detected 
in the primary tumor, but not detected 
in the metastatic nodule. We then 
administered gefitinib again. Both the 
primary tumor and metastatic nod-
ules responded to gefitinib (Fig. 1). 
Gefitinib has been continued for 3 
months.
gene are used as predictive markers 
for the effectiveness of specific thera-
pies such as epidermal growth factor 
receptor tyrosine kinase inhibitor and 
anaplastic lymphoma kinase inhibitor 
therapies. Researchers and now clini-
cians each emphasize that predictive 
factors and prognostic factors have 
different meanings; a prognostic fac-
tor provides information on outcome, 
independent of the therapy that is 
used, whereas a predictive factor pro-
vides information on outcome with 
regard to a specific therapy.3
A concern that arises is that we 
also use TNM classification for the 
decision of lung cancer resection. In 
the setting of this decision, we do 
not use TNM classification as a pre-
dictive factor for treatment-specific 
outcome. Mountain, et al.4 stated that 
the purpose of staging was to classify 
patients according to the anatomi-
cal extent or biological severity of 
their disease. Numerous efforts have 
been made to determine how stag-
ing clearly differs from each other in 
TNM classification, the 7th revision 
of which accurately reflects the prog-
nosis of patients with lung cancer. 
A question arises as to whether the 
decision of lung cancer resection is 
justified on the basis of a prognostic 
factor. It may be necessary to reassess 
the usage of TNM classification as a 
predictive factor in the decision of 
lung cancer resection.
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can be adopted, based on the result of 
rebiopsy.
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Our present case has shown spa-
tiotemporal T790M heterogeneity in an 
individual patient with EGFR-mutant 
non–small-cell lung cancer. One year after 
gefitinib-free interval, T790M status was 
distinct between the primary tumor and 
the metastatic nodule. T790M is medi-
ated by tyrosine kinase inhibitor (TKI)-
exposure, and TKI-withdrawal reduces 
the proportion of T790M-harboring cells 
in an EGFR-mutant tumor.2 T790M-
negative cancer cells might have grown 
in the metastatic nodule during gefi-
tinib withdrawal. Interestingly, both the 
primary tumor and metastatic nodules 
responded to gefitinib. It is natural that 
the T790M-negative metastatic nodules 
responded to gefitinib, but it is curious 
that T790M-positive primary tumor also 
responded. In preclinical data, erlotinib 
sensitivity decreases as T790M-positive 
cancer cells occupy from 10 to 25% in a 
mixed population of sensitive and resis-
tant cells.2 Tumors harboring low levels 
of T790M can still respond to EGFR-
TKI.3 A highly sensitive polymerase 
chain reaction method could detect a 
small portion (<10–25%) of T790M-
positive cells in the primary tumor.
T790M status is spatiotempo-
rally heterogeneous because of selec-
tive pressure from TKI. Local ablative 
therapies and EGFR-TKI rechallenge 
FIGURE 1.  Chest computed tomog-
raphy (CT) before gefitinib therapy: 
(A) T790M-positive primary tumor 
(arrow) and (B) T790M-negative 
pulmonary metastasis (arrow-
head). Chest CT 2 months later: 
(C) the responding primary tumor 
(arrow) and (D) metastatic nodule 
(arrowhead).
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To the Editor:
As a lung cancer survivor, pas-
sionate advocate for lung cancer 
patients around the world and founder 
of two lung cancer foundations—
the Bonnie J. Addario Lung Cancer 
Foundation and the Addario Lung 
Cancer Medical Institute (ALCMI)—I 
would like to respond to and commend 
Dr. David Carbone’s editorial in the 
Journal of Thoracic Oncology (An era 
of lung cancer iconoclasts. 2014:9). Dr. 
Carbone highlights the opportunities 
